<p>Cowa LLC 在第二季度收購了 Eli Lilly and Company（紐約證券交易所代碼：LLY - 免費報告）的新股份，根據該公司最近向證券交易委員會提交的 13F 表格。該公司收購了 282 股，價值約為 220,000 美元。</p>
<ul>
<li>一項宏偉的人工智能投資？Stanley Druckenmiller 的最新科技動態</li>
</ul>
<p>其他幾家對沖基金最近也買賣了 LLY 的股票。Braun Bostich &amp; Associates Inc.在第二季度將其在 Eli Lilly and Company 的持股增加了 2.5%。Braun Bostich &amp; Associates Inc.現在擁有 527 股該公司的股票，價值 411,000 美元，此前在上個季度又購買了 13 股。Rise Advisors LLC 在第二季度將其在 Eli Lilly and Company 的持股增加了 1.8%。Rise Advisors LLC 現在擁有 732 股該公司的股票，價值 571,000 美元，此前在上個季度又收購了 13 股。Occidental Asset Management LLC 在第二季度將其在 Eli Lilly and Company 的股份增加了 0.7%。Occidental Asset Management LLC 現在擁有 1,966 股該公司的股票，價值 1,533,000 美元，此前在上個季度又購買了 13 股。New Insight Wealth Advisors 在第二季度將其在 Eli Lilly and Company 的股份增加了 3.4%。New Insight Wealth Advisors 現在擁有 394 股該公司的股票，價值 307,000 美元，此前在上個季度又購買了 13 股。最後，Dash Acquisitions Inc.在第二季度將其在 Eli Lilly and Company 的持股增加了 2.8%。Dash Acquisitions Inc.現在擁有 485 股該公司的股票，價值 387,000 美元，此前在上個季度又購買了 13 股。82.53% 的股票由機構投資者和對沖基金持有。</p>
<p>獲取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
<h2>分析師升級和降級</h2>
<p>一些股票研究分析師最近對 LLY 股票發佈了報告。滙豐銀行在 10 月 1 日的報告中將 Eli Lilly and Company 的目標價格從 700.00 美元上調至 800.00 美元。Cantor Fitzgerald 在 10 月 31 日的研究報告中將 Eli Lilly and Company 的目標價格從 925.00 美元上調至 985.00 美元，並給予該股票 “超配” 評級。瑞銀集團在 11 月 7 日的研究報告中將 Eli Lilly and Company 的目標價格從 895.00 美元上調至 1,080.00 美元，並給予該公司 “買入” 評級。Berenberg Bank 在 9 月 17 日的研究報告中重申了 “持有” 評級，並將 Eli Lilly and Company 的目標價格設定為 830.00 美元（之前為 970.00 美元）。最後，斯科舍銀行在 11 月 13 日的報告中開始覆蓋 Eli Lilly and Company。他們對該股票設定了 “行業表現優於大盤” 的評級和 1,165.00 美元的目標價格。三位分析師給予該股票 “強烈買入” 評級，十五位分析師給予 “買入” 評級，七位分析師給予 “持有” 評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “適度買入”，共識目標價格為 1,027.95 美元。</p>
<ul>
<li>HIMS 經歷了過山車般的旅程。投資者應該加入嗎？</li>
</ul>
<p><strong>獲取我們關於 Eli Lilly and Company 的最新股票報告</strong></p>
<h2>Eli Lilly and Company 股票表現</h2>
<p>紐約證券交易所 LLY 的股票在週五開盤價為 1,058.05 美元。Eli Lilly and Company 的 12 個月低點為 623.78 美元，12 個月高點為 1,066.65 美元。該公司的市值為 1.00 萬億美元，市盈率為 69.15，市盈率/增長比率為 1.21，貝塔值為 0.43。該公司的 50 日移動平均線為 855.89 美元，200 日移動平均線為 787.66 美元。該公司的速動比率為 1.00，流動比率為 1.28，債務與股本比率為 1.86。</p>
<ul>
<li>年初至今下跌 45%，Novo Nordisk 引發價格戰</li>
</ul>
<p>Eli Lilly and Company（紐約證券交易所代碼：LLY - 獲取免費報告）最近在 10 月 30 日宣佈了其季度財報。該公司報告每股收益（EPS）為 7.02 美元，超過了共識預期的 6.42 美元，超出 0.60 美元。Eli Lilly and Company 的淨利潤率為 25.91%，股本回報率為 92.72%。該公司在本季度的收入為 176 億美元，而共識預期為 160.9 億美元。去年同期，該公司每股收益為 1.18 美元。Eli Lilly and Company 的季度收入同比增長 53.9%。Eli Lilly and Company 已將其 2025 財年的指導目標設定為 23.000-23.700 EPS。分析師平均預計 Eli Lilly and Company 在當前年度將發佈 23.48 EPS。</p>
<h2>Eli Lilly and Company 宣佈分紅</h2>
<p>該公司最近還披露了一項季度分紅，將於 12 月 10 日（星期三）支付。11 月 14 日（星期五）的股東將獲得每股 1.50 美元的分紅。除息日為 11 月 14 日（星期五）。這代表着每年 6.00 美元的分紅和 0.6% 的分紅收益率。Eli Lilly and Company 的派息比率目前為 29.35%。</p>
<h2>關於 Eli Lilly and Company</h2>
<p>（免費報告）</p>
<p>Eli Lilly and Company 在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素 lispro、胰島素 lispro 原料、胰島素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；Zepbound 用於肥胖。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更喜歡的五隻股票超過 Eli Lilly and Company</li>
<li>複利是如何計算的？</li>
<li>一項宏偉的人工智能投資？Stanley Druckenmiller 的最新科技動態</li>
<li>如何使用 MarketBeat 分紅計算器</li>
<li>12 位分析師剛剛提高了 CrowdStrike 的目標——他們預見了什麼</li>
<li>零售投資者如何交易多倫多證券交易所（TSX）？</li>
<li>Palo Alto Networks 的股票剛剛回調——這是一個理想的買入區嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在禮來公司嗎？</h2>
<p>在考慮禮來公司之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前立即購買的股票……而禮來公司並不在名單上。</p>
<p>儘管禮來公司目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

禮來

<p>Cowa LLC 收購了 282 股禮來，價值 220,000 美元。分析師們發佈了各種評級，普遍目標價為 1,027.95 美元。禮來的股票開盤價為 1,058.05 美元，12 個月最高價為 1,066.65 美元。該公司報告的季度每股收益為 7.02 美元，超出預期，收入為 176 億美元，同比增長 53.9%</p>

<p>Cowa LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm acquired 282 shares of the company's stock, valued at approximately $220,000.</p>
<div class="lb-trans"><p>Cowa LLC 在第二季度收購了 Eli Lilly and Company（紐約證券交易所代碼：LLY - 免費報告）的新股份，根據該公司最近向證券交易委員會提交的 13F 表格。該公司收購了 282 股，價值約為 220,000 美元。</p>
</div><ul>
<li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li>
</ul>
<div class="lb-trans"><ul>
<li>一項宏偉的人工智能投資？Stanley Druckenmiller 的最新科技動態</li>
</ul>
</div><p>Several other hedge funds also recently bought and sold shares of LLY. Braun Bostich &amp; Associates Inc. increased its holdings in Eli Lilly and Company by 2.5% in the second quarter. Braun Bostich &amp; Associates Inc. now owns 527 shares of the company's stock worth $411,000 after buying an additional 13 shares during the last quarter. Rise Advisors LLC grew its position in Eli Lilly and Company by 1.8% in the second quarter. Rise Advisors LLC now owns 732 shares of the company's stock worth $571,000 after acquiring an additional 13 shares in the last quarter. Occidental Asset Management LLC increased its stake in shares of Eli Lilly and Company by 0.7% during the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company's stock worth $1,533,000 after purchasing an additional 13 shares during the last quarter. New Insight Wealth Advisors increased its stake in shares of Eli Lilly and Company by 3.4% during the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company's stock worth $307,000 after purchasing an additional 13 shares during the last quarter. Finally, Dash Acquisitions Inc. raised its holdings in shares of Eli Lilly and Company by 2.8% during the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company's stock valued at $387,000 after purchasing an additional 13 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他幾家對沖基金最近也買賣了 LLY 的股票。Braun Bostich &amp; Associates Inc.在第二季度將其在 Eli Lilly and Company 的持股增加了 2.5%。Braun Bostich &amp; Associates Inc.現在擁有 527 股該公司的股票，價值 411,000 美元，此前在上個季度又購買了 13 股。Rise Advisors LLC 在第二季度將其在 Eli Lilly and Company 的持股增加了 1.8%。Rise Advisors LLC 現在擁有 732 股該公司的股票，價值 571,000 美元，此前在上個季度又收購了 13 股。Occidental Asset Management LLC 在第二季度將其在 Eli Lilly and Company 的股份增加了 0.7%。Occidental Asset Management LLC 現在擁有 1,966 股該公司的股票，價值 1,533,000 美元，此前在上個季度又購買了 13 股。New Insight Wealth Advisors 在第二季度將其在 Eli Lilly and Company 的股份增加了 3.4%。New Insight Wealth Advisors 現在擁有 394 股該公司的股票，價值 307,000 美元，此前在上個季度又購買了 13 股。最後，Dash Acquisitions Inc.在第二季度將其在 Eli Lilly and Company 的持股增加了 2.8%。Dash Acquisitions Inc.現在擁有 485 股該公司的股票，價值 387,000 美元，此前在上個季度又購買了 13 股。82.53% 的股票由機構投資者和對沖基金持有。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Eli Lilly and Company</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級和降級</h2>
</div><p>A number of equities research analysts recently issued reports on LLY shares. HSBC upped their price objective on shares of Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Cantor Fitzgerald upped their price target on Eli Lilly and Company from $925.00 to $985.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, October 31st. UBS Group raised their price objective on Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, November 7th. Berenberg Bank reaffirmed a &#34;hold&#34; rating and set a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Finally, Scotiabank assumed coverage on Eli Lilly and Company in a report on Thursday, November 13th. They set a &#34;sector outperform&#34; rating and a $1,165.00 price target on the stock. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $1,027.95.</p>
<div class="lb-trans"><p>一些股票研究分析師最近對 LLY 股票發佈了報告。滙豐銀行在 10 月 1 日的報告中將 Eli Lilly and Company 的目標價格從 700.00 美元上調至 800.00 美元。Cantor Fitzgerald 在 10 月 31 日的研究報告中將 Eli Lilly and Company 的目標價格從 925.00 美元上調至 985.00 美元，並給予該股票 “超配” 評級。瑞銀集團在 11 月 7 日的研究報告中將 Eli Lilly and Company 的目標價格從 895.00 美元上調至 1,080.00 美元，並給予該公司 “買入” 評級。Berenberg Bank 在 9 月 17 日的研究報告中重申了 “持有” 評級，並將 Eli Lilly and Company 的目標價格設定為 830.00 美元（之前為 970.00 美元）。最後，斯科舍銀行在 11 月 13 日的報告中開始覆蓋 Eli Lilly and Company。他們對該股票設定了 “行業表現優於大盤” 的評級和 1,165.00 美元的目標價格。三位分析師給予該股票 “強烈買入” 評級，十五位分析師給予 “買入” 評級，七位分析師給予 “持有” 評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “適度買入”，共識目標價格為 1,027.95 美元。</p>
</div><ul>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
</ul>
<div class="lb-trans"><ul>
<li>HIMS 經歷了過山車般的旅程。投資者應該加入嗎？</li>
</ul>
</div><p><strong>Get Our Latest Stock Report on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Eli Lilly and Company 的最新股票報告</strong></p>
</div><h2>Eli Lilly and Company Stock Performance</h2>
<div class="lb-trans"><h2>Eli Lilly and Company 股票表現</h2>
</div><p>Shares of NYSE LLY opened at $1,058.05 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,066.65. The company has a market cap of $1.00 trillion, a P/E ratio of 69.15, a P/E/G ratio of 1.21 and a beta of 0.43. The business's 50 day moving average is $855.89 and its two-hundred day moving average is $787.66. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.</p>
<div class="lb-trans"><p>紐約證券交易所 LLY 的股票在週五開盤價為 1,058.05 美元。Eli Lilly and Company 的 12 個月低點為 623.78 美元，12 個月高點為 1,066.65 美元。該公司的市值為 1.00 萬億美元，市盈率為 69.15，市盈率/增長比率為 1.21，貝塔值為 0.43。該公司的 50 日移動平均線為 855.89 美元，200 日移動平均線為 787.66 美元。該公司的速動比率為 1.00，流動比率為 1.28，債務與股本比率為 1.86。</p>
</div><ul>
<li>Down 45% Year-to-Date, Novo Nordisk Ignites a Price War</li>
</ul>
<div class="lb-trans"><ul>
<li>年初至今下跌 45%，Novo Nordisk 引發價格戰</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter last year, the company posted $1.18 earnings per share. Eli Lilly and Company's quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.</p>
<div class="lb-trans"><p>Eli Lilly and Company（紐約證券交易所代碼：LLY - 獲取免費報告）最近在 10 月 30 日宣佈了其季度財報。該公司報告每股收益（EPS）為 7.02 美元，超過了共識預期的 6.42 美元，超出 0.60 美元。Eli Lilly and Company 的淨利潤率為 25.91%，股本回報率為 92.72%。該公司在本季度的收入為 176 億美元，而共識預期為 160.9 億美元。去年同期，該公司每股收益為 1.18 美元。Eli Lilly and Company 的季度收入同比增長 53.9%。Eli Lilly and Company 已將其 2025 財年的指導目標設定為 23.000-23.700 EPS。分析師平均預計 Eli Lilly and Company 在當前年度將發佈 23.48 EPS。</p>
</div><h2>Eli Lilly and Company Announces Dividend</h2>
<div class="lb-trans"><h2>Eli Lilly and Company 宣佈分紅</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company's payout ratio is presently 29.35%.</p>
<div class="lb-trans"><p>該公司最近還披露了一項季度分紅，將於 12 月 10 日（星期三）支付。11 月 14 日（星期五）的股東將獲得每股 1.50 美元的分紅。除息日為 11 月 14 日（星期五）。這代表着每年 6.00 美元的分紅和 0.6% 的分紅收益率。Eli Lilly and Company 的派息比率目前為 29.35%。</p>
</div><h2>About Eli Lilly and Company</h2>
<div class="lb-trans"><h2>關於 Eli Lilly and Company</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>Eli Lilly and Company 在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素 lispro、胰島素 lispro 原料、胰島素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；Zepbound 用於肥胖。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>How is Compound Interest Calculated?</li>
<li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li>
<li>How to Use the MarketBeat Dividend Calculator</li>
<li>12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更喜歡的五隻股票超過 Eli Lilly and Company</li>
<li>複利是如何計算的？</li>
<li>一項宏偉的人工智能投資？Stanley Druckenmiller 的最新科技動態</li>
<li>如何使用 MarketBeat 分紅計算器</li>
<li>12 位分析師剛剛提高了 CrowdStrike 的目標——他們預見了什麼</li>
<li>零售投資者如何交易多倫多證券交易所（TSX）？</li>
<li>Palo Alto Networks 的股票剛剛回調——這是一個理想的買入區嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在禮來公司嗎？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮禮來公司之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前立即購買的股票……而禮來公司並不在名單上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管禮來公司目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Cowa LLC 購買了 282 股 Eli Lilly 公司的股票$LLY